Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01538381|
Recruitment Status : Completed
First Posted : February 24, 2012
Last Update Posted : October 12, 2016
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Squamous Cell of Head and Neck||Drug: Afatinib Other: Observation||Phase 2|
This is a randomized, multicenter early phase II trial exploring the pre-operative activity of afatinib vs. nontreatment. The study includes an early monitoring of the surgical co-morbidities for patients treated with afatinib and accrual may be stopped prematurely according to a pre-defined safety stopping rule.
Patients will be randomized with a 5:1 ratio, between the two arms: afatinib and 'no treatment'. It is intended to include a total of 30 eligible patients out of which 25 patients will be randomized into the afatinib arm.
Patients allocated to the 'no treatment' arm will mainly serve as a reference to interpret the results of the translational research part of the study although no formal comparison between the afatinib arm and the 'no treatment' arm is intended.
Patients will be first registered into the EORTC system after signing the informed consent form. The site will have to complete all the study related procedures within 4 weeks prior randomization and all eligibility criteria should be met before the patient can be randomized into the study.
The registration of patients will proceed with slots for patients which will be opened or closed based on the randomization of patients into the afatinib arm. Starting with 3 free slots, an additional slot will become available for each patient randomized to the 'no treatment' arm.
Registration will be paused after three completes the 4 week observation period after surgery. Similar action will be done after the next 3 patients have been entered into the afatinib arm.
Once the first 6 patients in the afatinib arm have been observed for surgical toxicities of grade ≥ 3 for 4 weeks following surgery, the slot system will cease to operate.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Neoadjuvant Afatinib Based Treatment Strategies Followed by Surgery in Squamous Cell Carcinoma of the Head and Neck: an EORTC NOCI-HNCG Window Study.|
|Study Start Date :||July 2012|
|Primary Completion Date :||August 2015|
|Study Completion Date :||August 2015|
Afatinib given orally for 2 weeks after randomization till day -1 prior to surgery (day 0) at a dose of 40 mg/day
Afatinib for 2 weeks at a dose of 40 mg/day
No treatment only observation
- Reduction of tumor Standardised Uptake Volume as assessed by FDGPET [ Time Frame: Baseline and after two weeks of treatment ]Afatinib will be given orally for 2 weeks from the day of randomization until day -1 prior to surgery at a dose of 40 mg/day.Pre-treatment biopsies and blood samples will be harvested during the regular diagnosis staging procedure and at surgery.FDG-PET/CT-scan and MRIs will be performed before treatment (before day -15) and the day before surgery.The primary outcome measure is the reduction in the tumor standardised uptake volume as assessed by FDGPET
- Evaluation of tumour response to treatment by different imaging modalities like DWIMRI and DCEMRI [ Time Frame: Baseline and after two weeks of treatment ]
Response after 2 weeks of treatment, prior to surgery, evaluated by:
- RECIST v1.1 using conventional imaging
- Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI)
- Diffusion Weighted Imaging Magnetic Resonance Imaging (DWI MRI)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01538381
|Institut Jules Bordet|
|Brussels, Belgium, 1000|
|Cliniques Universitaires St. Luc|
|Brussels, Belgium, 1200|
|U.Z. Leuven - Campus Gasthuisberg|
|Leuven, Belgium, 3000|
|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori|
|Milano, Italy, 20133|
|Study Chair:||Jean-Pascal Machiels, MD||European Organisation for Research and Treatment of Cancer - EORTC|
|Principal Investigator:||Lisa Licitra, MD||European Organisation for Research and Treatment of Cancer - EORTC|